Paper Details

  1. Home
  2. Paper Details

Pulmonary Safety and Tolerability of Inhaled Levodopa (CVT-301) Administered to Patients with Parkinson's Disease.

Author: BatyckyRichard, CorbinAnn, LeWittPeter A, MurckHarald, PahwaRajesh, SedkovAlexander

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

CVT-301, an inhaled levodopa (LD) formulation, is under development for relief of OFF periods in Parkinson's disease (PD). This study evaluated pulmonary function in patients treated with a single dose of CVT-301 or placebo for 3 hours, or received multiple doses/day for 4 weeks.
Paper Details　
Original Abstract of the Article :
CVT-301, an inhaled levodopa (LD) formulation, is under development for relief of OFF periods in Parkinson's disease (PD). Previously, we reported that CVT-301 improved OFF symptoms relative to placebo. In this study, we evaluate pulmonary function in patients treated with a single dose of CVT-301 o...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5994675/

データ提供：米国国立医学図書館（NLM）

Inhaled Levodopa: A Promising Approach for Parkinson's Disease

Managing [Parkinson's disease (PD)] is a complex endeavor, with researchers constantly seeking innovative therapies to improve patient outcomes. This study investigates the [pulmonary safety and tolerability] of [inhaled levodopa (CVT-301)], a novel formulation of [levodopa] under development for the treatment of [OFF periods] in PD. The study aims to assess the potential pulmonary effects of this inhaled medication.

Inhaled Levodopa: A Breath of Fresh Air for PD Patients

The study found that [CVT-301] was generally [well-tolerated] and did not cause significant adverse pulmonary effects in patients with PD. The results indicate that inhaled levodopa could be a safe and effective treatment option for managing [OFF periods] in PD patients. Further research is needed to confirm its long-term safety and efficacy.

A New Frontier in Parkinson's Treatment: Inhaled Levodopa

The study's findings offer hope for PD patients, providing a potential new approach to managing [OFF periods] that could improve quality of life. The development of [inhaled levodopa] could revolutionize [Parkinson's treatment], offering a convenient and potentially more effective way to deliver this essential medication.

Dr.Camel's Conclusion

Just as the desert wind carries scents of distant spices, inhaled levodopa could deliver a vital medication directly to PD patients. This study suggests that inhaled levodopa is a promising new frontier in Parkinson's treatment, offering a potentially safer and more effective way to manage the disease. With further research, this innovative approach could bring a breath of fresh air to the lives of those living with Parkinson's disease.

Date :
  1. Date Completed 2019-06-10
  2. Date Revised 2019-06-13
Further Info :

Pubmed ID

29161531

DOI: Digital Object Identifier

PMC5994675

Related Literature

Article Analysis
・Effects of levodopa oral inhalation
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.